(Q33748037)

29 July 2017

1 reference

title

Risks and benefits of aromatase inhibitors in postmenopausal breast cancer (English)

1 reference

29 July 2017

L B Michaud

1

1 reference

29 July 2017

A U Buzdar

series ordinal

2

1 reference

29 July 2017

publication date

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

21

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

297-309

1 reference

Second generation aromatase inhibitor--4-hydroxyandrostenedione

29 July 2017

cites work

1 reference

12 December 2020

1 reference

12 December 2020

Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging

1 reference

12 December 2020

Aromatase inhibition for breast cancer treatment

1 reference

12 December 2020

Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane

1 reference

12 December 2020

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

1 reference

12 December 2020

Exemestane (FCE 24304), a new steroidal aromatase inhibitor

1 reference

12 December 2020

Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats

1 reference

12 December 2020

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

1 reference

12 December 2020

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

12 December 2020

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

1 reference

12 December 2020

Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione

1 reference

12 December 2020

Aromatase inhibitors and breast cancer

1 reference

12 December 2020

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

12 December 2020

Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer

1 reference

12 December 2020

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

12 December 2020

Measurement of Aromatisation by a Urine Technique Suitable for the Evaluation of Aromatase Inhibitorsin Vivo

1 reference

12 December 2020

Absolute bioavailability of letrozole in healthy postmenopausal women

1 reference

12 December 2020

Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats

1 reference

12 December 2020

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

1 reference

12 December 2020

Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy

1 reference

12 December 2020

Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma

1 reference

12 December 2020

Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

12 December 2020

Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy

1 reference

12 December 2020

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

12 December 2020

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

1 reference

12 December 2020

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer

1 reference

12 December 2020

Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole

1 reference

12 December 2020

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

12 December 2020

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

12 December 2020

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

1 reference

12 December 2020

Arimidex: a potent and selective fourth-generation aromatase inhibitor

1 reference

12 December 2020

Aromatase inhibitors as potential cancer chemopreventives.

1 reference

12 December 2020

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

12 December 2020

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer

1 reference

12 December 2020

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

12 December 2020

10.2165/00002018-199921040-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1040073262

0 references

1 reference